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Preoperative Standard Oral Nutrition
Supplements vs Immunonutrition: Results of a
Systematic Review and Meta-Analysis
Refaat A Hegazi, MD, PhD, MPH, MS, Deborah S Hustead, PhD, David C Evans, MD, FACSSUMMARY
Multiple studies and meta-analyses have suggested some
benefit to immunonutrition (IN) supplements. These
studies have often included pre- and post-operative regi-
mens and have utilized inconsistent controls ranging from
standard non-supplemented oral diets to high-quality isoni-
trogenous controls. This study aims to compare outcomes
after preoperative nutritional supplementation with IN vs.
standard oral nutritional supplements (ONS) or a regular
diet without supplements.
We performed a systematic literature review. 8 ran-
domized controlled trials (RCTs) of preoperative IN vs.
ONS were identified and 9 RCTs of IN vs. no supple-
ments were also identified. Meta-analysis was performed
for reported outcomes including wound infection, infec-
tious and non-infectious complications, and length of
stay (LOS). The meta-analysis was prepared in accor-
dance with Preferred Reporting of Systematic Reviews
and Meta-Analyses (PRISMA) recommendations.
We identified 561 patients in 8 RCTs of preoperative
IN vs. ONS. 895 patients were identified in 9 RCTs of
IN vs. no supplements. When compared to ONS, preop-
erative IN was not associated with reduced wound infec-
tion (OR 0.97, 95% Confidence Interval (CI) 0.45 to
2.11), all infectious complications (OR 0.71, 95% CI
0.30 to 1.68), non-infectious complications (OR 1.25,
95% CI 0.64 to 2.43), or LOS (mean difference 0.07
days, 95% CI 2.29 to 2.43). In RCTs controlled with
non-supplemented standard diets, preoperative IN was
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ference 2.22 days, 95% CI 2.99 to 1.45, p0.01).
In conclusion, there was no evidence for IN to be su-
perior to ONS on several key clinical outcomes. There-
fore standard ONS may offer an alternative to IN for
preoperative nutritional supplementation.INTRODUCTION
Surgery poses a catabolic stress characterized by the pres-
ence of an inflammatory response associated with deple-
tion of conditionally essential nutrients, which leads to a
dysregulated immune response that increases the risk for
postoperative complications, especially infections. The
role of immunonutrition (IN) in the nutritional manage-
ment of surgical patients has been recommended by major
society guidelines. One of only two grade-A recommenda-
tions by the 2009 American Society for Parenteral and
Enteral Nutrition/Society of Critical Care Medicine
guidelines was for the use of IN in surgical ICU patients.1
Within the last few years, several meta-analyses have
examined this topic. The meta-analysis by Drover and
colleagues2 showed that IN improved clinical outcomes,
especially postoperative infections, as compared with con-
trols in the perioperative period. This meta-analysis com-
bined studies with standard nutritional supplements and
standard nonsupplemented diets as the control groups
without clear differentiation between the two. More
recent meta-analyses have suggested that both the dietary
composition of the nutritional supplementation and
timing of IN are equally important in determining the
beneficial effect of IN. Osland and colleagues suggested
that the evidence of IN is strong when it is used in the
postoperative as compared with preoperative period.3 In
addition, Marik and Zaloga suggested that the effect of
IN depends on the nutrient composition of the IN for-
mula and that the most important outcomes benefits arise
from IN formulations supplemented with fish oil and
arginine in high-risk surgical patients.4
Fish oilederived omega-3 fatty acids displacing the
arachidonic acid of the cell membrane of immune cells
attenuate the production of inflammatory prostaglandins
and prostacyclins and reduce the cytotoxicity ofhttp://dx.doi.org/10.1016/j.jamcollsurg.2014.06.016
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pentanoic and docohexanoic acids are the precursors of
resolvins, shown to reduce cellular inflammation by
inhibiting the transportation of inflammatory cells and
mediators to the site of inflammation.5 The conditionally
essential amino acid arginine can function as a precursor
of proline and polyamines, which are essential for tissue
repair and wound healing. Arginine is also crucial for
the integrity and function of immune cells. In addition,
arginine is an important immune-modulating nutrient
as a precursor of nitric oxide synthesis. Studies have
shown that arginine deficiency occurs as a result of surgi-
cal injury.6 Immunonutrition supplements have varying
concentrations of these key ingredients and the ideal dos-
ages are not well defined. In fact, the relative dosages of
the immune-modulating ingredients even vary at times
from country to country in products made by the same
manufacturer. No consensus exists about standard dos-
ages for these ingredients and immunonutrients are
frequently included (albeit in lower quantities) in stan-
dard oral nutritional supplements (ONS).
The role of standard ONS for preoperative nutritional
optimization is not well delineated. Standard ONS formu-
lations are typically high in protein and supplemented with
vitamins and minerals. They are inexpensive, widely distrib-
uted, and commonly used by patients who desire nutri-
tional supplementation when recovering from an illness.
Data describing the effects of standard ONS in the preop-
erative period are scarce. Whether the clinical benefits of
preoperative IN are substantial when compared with isoca-
loric and isonitrogenous standard nutritional formulations
is an unanswered question. It might be that the benefit of
preoperative IN supplementation can be achieved by sup-
plementation with high levels of protein and standard vita-
mins and minerals, not the additional arginine, fish oil, and
other immunonutrients. In the current meta-analysis, we
examine the effects of IN vs standard nutritional supple-
ments and vs regular diet with no supplements.
METHODS
Inclusion and exclusion criteria
Studies of the preoperative provision of ONS identified as
IN or immune-modulating as compared with standardoral nutrition formulas or no supplements were reviewed.
Only randomized controlled trials (RCTs) with primary
comparisons between the nutrition interventions were
included. For inclusion, studies should have reported
on clinically relevant outcomes pertaining to the postop-
erative period, namely wound infections, infectious and
noninfectious complications, and length of hospital
stay. Retrospective studies and those using perioperative
IN or parenteral nutrition were excluded.
Study identification
We conducted a systematic review of the published litera-
ture to identify all relevant RCTs that used IN preopera-
tively. Using text word or MeSH headings containing
“randomized,” “blind,” “clinical trial,” “immunonutri-
tion,” “immunemodulating,” and “human,” we performed
searches for relevant articles on Analytical Abstracts, BIO-
SIS Previews, Embase, Foodline: SCIENCE, FSTA,
MEDLINE, electronic databases Cochrane Controlled
Trials Register from 1990 to January 2014.
The data were prepared in accordance with the
Preferred Reporting of Systematic Reviews and Meta-
Analyses statement7 (Fig. 1). Data extraction and critical
appraisal of identified studies were carried out by the au-
thors for compliance with inclusion criteria. The authors
were not blinded to the source of the document or
authorship for the purpose of data extraction.
Statistical analysis
Among the primary outcomes of interest was infectious
complications or the number of patients with infectious
complications. We used infectious complications as defined
by the original authors. Secondary outcomes included
wound infections, noninfectious complications, and hospital
length of stay.
For data expressed as an event, the numbers of pa-
tients with the event and sample size for each group in
each study were entered into the analyses. All data re-
ported from the individual studies are expressed as an
odds ratio (OR) with the associated 95% CI. For length
of stay (LOS), the mean, SD, and number of patients for
each group were entered into the analyses. The differ-
ence in the means, SEs, and associated 95% CIs were
calculated. A random effects model was used to calculate
all summary parameters. The random effects model is
used when studies are not functionally similar and/or
cannot be assumed to all have a common effect size. Un-
der the random effects model, the assumption is that
each study is estimating a unique effect, and therefore,
the null hypothesis is that the mean of the true effects
is zero. The studies included in this analysis contained
different populations (eg, cancer and noncancer),
Figure 1. Preferred Reporting of Systematic Reviews and Meta-Analyses statement describing the iden-
tification, inclusion, and exclusion of randomized controlled trials evaluating the effect of preoperative
immunonutrition on postoperative clinical outcomes compared with standard oral nutrition supplements
and no supplements.
1080 Hegazi et al Preoperative Nutrition Meta-Analysis J Am Coll Surgdifferent supplement durations, and different control
ONS products, therefore, a priori it was decided they
were heterogeneous and the random effects model was
appropriate. Forest plots were prepared to graphically
represent the meta-analysis; the area of each square is
proportional to the study’s weight in the meta-analysis
and the diamond depicts the overall summary and
95% CI of the analysis. Analyses were performed using
the software package Comprehensive Meta-Analysis,
version 2 (Biostat, Inc.).RESULTS
Sixteen studies of the use of preoperative IN were identi-
fied. One study8 was excluded from our analysis because
it was a retrospective analysis of prospectively collected
data. The Preferred Reporting of Systematic Reviews and
Meta-Analyses flow diagram in Figure 1 summarizes theprocess. Of the 15 studies, 2 had multiple arms, which
allowed them to be used in both subsets of analyses.
Sufficient data were available for the analysis for 4 clinically
relevant outcomes: wound infections, all infectious compli-
cations, noninfectious complications, and LOS. Five hun-
dred and sixty-one patients in 8 RCTs9-16 of preoperative
IN vs ONS were identified (Table 1) and 895 patients in
9 RCTs of IN vs no supplements were also identified
(Table 2).11,14,17-23Preoperative immunonutrition vs standard oral
nutritional supplements
When compared with ONS, preoperative IN was not
associated with a reduced rate of wound infection
(OR ¼ 0.97; 95% CI, 0.45e2.11; p ¼ 0.94), all infec-
tious complications (OR ¼ 0.71; 95% CI, 0.30e1.68;
p ¼ 0.44), noninfectious complications (OR ¼ 1.25;
Table 1. Preoperative Use of Immunonutrition vs Standard Oral Nutrition Supplements Study Characteristics
First author, year,
country Study population Study design
Immunonutrition,
n
Oral nutrition
supplements, n Study end points
Wachtler, 1995,
Germany9
Upper GI surgery
for cancer
IN preoperatively for 5 d vs isocaloric
ONS for 5 d preoperatively
20 20 Functional parameters of peripheral
blood leukocytes
McCarter, 1998,
United States10
GI CA IN preoperatively for 7 d vs ONS
preoperatively for 7 d vs ONS with
arginine preoperatively for 7 d
13 11 Postoperative immunologic function
and complications, and LOS
Braga, 2002, Italy11 Colorectal CA IN preoperatively for 5 d vs isocaloric/
isonitrogenous ONS preoperatively
for 5 d vs IN preoperatively for
5 d þ IN postoperatively vs no
supplementation
50 50 Immune response, gut oxygenation and
postoperative infections
Xu, 2006, China12 Colorectal or
GI CA
IN preoperatively for 7 d þ ONS
postoperatively vs ONS
preoperatively for 7 d þ ONS
postoperatively
30 30 Nutritional status, immunity, and incidence
of postoperative complications
Okamoto, 2009,
Japan13
Gastric CA IN preoperatively for 7 d
vs isoenergetic ONS preoperatively
for 7 d
30 30 Cellular immunity, duration of systemic
inflammatory response syndrome, and
postoperative complications
Gunerhan, 2009,
Turkey14
GI tumors, mix
of moderate
and severe
malnourished
IN preoperatively for 7 d vs ONS
preoperatively for 7 d vs normal
nutrition, isocaloric, isonitrogenous
to ONS
13 11 Cellular immunity parameters,
postoperative complications, LOS
Hu¨bner, 2012,
Switzerland15
GI surgery
NRS score 3
IN preoperatively for 5 d vs isocaloric
isonitrogenous ONS preoperatively
for 5 d
73 72 30-day complication rate, infections, LOS
Giger-Pabst, 2013,
Switzerland16
GI CA, well
nourished
(NRS score <3)
IN preoperatively for 3 d vs
isocaloric isonitrogenous ONS
preoperatively for 3 d
55 53 Postoperative infectious and noninfectious
complications, length of ICU stay, LOS,
antibiotic use
CA, cancer; GI, gastrointestinal; IN, immunonutrition; LOS, length of stay; NRS, Nutrition Risk Screening-2002; ONS, oral nutrition supplements.
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Table 2. Preoperative Use of Immunonutrition vs No Supplements Study Characteristics
First author, year, country Study population Study design
Immunonutrition,
n
No
supplements,
n Study end points
Braga, 2002, Italy11 Colorectal CA IN preoperatively for 5 d vs
isocaloric/isonitrogenous
ONS preoperatively for 5 d
vs IN preoperatively for 5 d þ
IN postoperatively vs no
supplementation
50 50 Immune response, gut oxygenation
and postoperative infections
Braga, 2002, Italy17 Malnourished (weight loss
10%), GI CA
IN preoperatively for 7 d þ ONS
postoperatively vs IN preoperatively
for 7 d þ IN postoperatively vs
postoperatively ONS
50 50 Postoperative complications
and LOS
Gianotti, 2002, Italy18 GI CA IN preoperatively for 5 d vs IN
preoperatively þ IN postoperatively
vs no artificial nutrition
102 102 Postoperative infections and LOS,
nutritional parameters, and gut
function
Horie, 2006, Japan19 Colorectal CA, Without
malnutrition
IN preoperatively for 5 d vs
control group
33 34 Surgical site infection and
postoperative inflammation
Gunerhan, 2009, Turkey14 GI tumors, mix of
moderate and severe
malnourished
IN preoperatively for 7 d vs ONS
preoperatively for 7 d vs normal
nutrition, isocaloric, isonitrogenous
to ONS
13 9 Cellular immunity parameters,
postoperative complications,
LOS
Mikagi, 2011, Japan20 Liver CA IN preoperatively for 5 d vs hospital
meals preoperatively for 5 d
13 13 Clinical outcomes, extent of
hepatectomy, operation time,
volume blood loss, Pringle
time, postoperative
complications and LOS
Fujitani, 2012, Japan21 GI CA, well nourished IN preoperatively for 5 days vs
No nutritional supplements
120 111 Surgical site infection, infectious
complications, postoperative
morbidity and CRP levels
Barker, 2013, Australia22 Malnourished and well
nourished, GI surgery
IN preoperatively for 5 d vs no
supplements
46 49 LOS, infectious and noninfectious
complications, ICU admission,
mortality, 30-day follow-up of
surgical wound required
antibiotics for healing,
and treatment costs
Aida, 2014, Japan23 Pancreaticoduodenectomy IN preoperatively for 5 d vs no
supplements
25 25 Operative complications and
immune responses
CA, cancer; CRP, C-reactive protein; GI, gastrointestinal; IN, immunonutrition; LOS, length of stay; ONS, oral nutrition supplements.
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Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value IN ONS
Wachtler (1995) 3.154 0.121 82.165 0.490 1 / 20 0 / 20
McCarter (1998) 5.000 0.215 116.035 0.316 2 / 13 0 / 11
Braga (2002a) 0.734 0.156 3.462 0.696 3 / 50 4 / 50
Xu (2006) 0.310 0.030 3.168 0.324 1 / 30 3 / 30
Okamoto (2009) 0.483 0.041 5.628 0.561 1 / 30 2 / 30
Gunerhan (2009) 2.813 0.422 18.735 0.285 5 / 13 2 / 11
Giger-Pabst (2013) 0.707 0.150 3.320 0.660 3 / 55 4 / 53
0.969 0.446 2.106 0.936
0.1 0.2 0.5 1 2 5 10
Favors IN Favors ONS
Overall
Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value IN ONS
McCarter (1998) 2.813 0.422 18.735 0.285 5 / 13 2 / 11
Braga (2002a) 0.290 0.102 0.819 0.020 6 / 50 16 / 50
Okamoto (2009) 0.196 0.038 1.020 0.053 2 / 30 8 / 30
Hubner (2012) 1.517 0.604 3.808 0.375 13 / 73 9 / 72
Giger-Pabst (2013) 0.832 0.295 2.348 0.728 8 / 55 9 / 53
0.710 0.300 1.684 0.437
0.1 0.2 0.5 1 2 5 10
Favors IN Favors ONS
Overall
A
B
Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value IN ONS
Braga (2002a) 1.362 0.289 6.426 0.696 4 / 50 3 / 50
Okamoto (2009) 1.000 0.226 4.431 1.000 4 / 30 4 / 30
Gunerhan (2009) 2.813 0.422 18.735 0.285 5 / 13 2 / 11
Giger-Pabst (2013) 1.075 0.414 2.791 0.882 11 / 55 10 / 53
1.247 0.640 2.431 0.517
0.1 0.2 0.5 1 2 5 10
Favors IN Favors ONS
Overall
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error limit limit p-Value IN ONS
McCarter (1998) 4.000 1.214 1.621 6.379 0.001 13 11
Braga (2002a) -2.500 0.757 -3.984 -1.016 0.001 50 50
Xu (2006) -3.000 0.893 -4.750 -1.250 0.001 30 30
Okamoto (2009) -1.200 3.596 -8.248 5.848 0.739 30 30
Gunerhan (2009) 2.320 5.146 -7.765 12.405 0.652 13 11
Hubner (2012) 3.000 2.382 -1.668 7.668 0.208 73 72
Giger-Pabst (2013) 0.400 0.982 -1.524 2.324 0.684 55 53
0.070 1.205 -2.292 2.433 0.953
-10.00 -5.00 0.00 5.00 10.00
Favors IN Favors ONS
Overall
C
D
Figure 2. Forest plot results of meta-analysis of preoperative immunonutrition (IN) vs standard oral
nutritionsupplements (ONS). (A)Preoperative immunonutrition (IN) vsstandardoralnutritionsupplements
(ONS) on wound infection using random effectsmodel. (B) Preoperative IN vs standard ONS on infectious
complications using random effects model. (C) Preoperative IN vs standard ONS on noninfectious com-
plications using random effects model. (D) Preoperative IN vs standard ONS on length of stay using
random effects model.
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Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper No 
ratio limit limit p-Value IN Supp
Braga (2002a) 0.574 0.130 2.545 0.465 3 / 50 5 / 50
Braga (2002b) 0.479 0.084 2.743 0.409 2 / 50 4 / 50
Gianotti (2002) 0.610 0.226 1.641 0.327 7 / 102 11 / 102
Horie (2006) 0.080 0.004 1.510 0.092 0 / 33 5 / 34
Gunerhan (2009) 1.250 0.211 7.414 0.806 5 / 13 3 / 9
Fujitani (2012) 1.564 0.623 3.930 0.341 13 / 120 8 / 111
Barker (2013) 0.476 0.149 1.517 0.209 5 / 46 10 / 49
Aida (2014) 0.351 0.079 1.554 0.168 3 / 25 7 / 25
0.689 0.432 1.098 0.117
0.1 0.2 0.5 1 2 5 10
Favors IN Favors No Supp
Overall
Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper No 
ratio limit limit p-Value IN Supp
Braga (2002a) 0.318 0.112 0.905 0.032 6 / 50 15 / 50
Braga (2002b) 0.603 0.223 1.634 0.320 8 / 50 12 / 50
Gianotti (2002) 0.364 0.180 0.737 0.005 14 / 102 31 / 102
Mikagi (2011) 0.309 0.011 8.300 0.484 0 / 13 1 / 13
Fujitani (2012) 1.037 0.570 1.888 0.905 30 / 120 27 / 111
Aida (2014) 0.259 0.079 0.847 0.025 7 / 25 15 / 25
0.494 0.295 0.827 0.007
0.1 0.2 0.5 1 2 5 10
Favors IN Favors No Supp
Overall
Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper No 
ratio limit limit p-Value IN Supp
Braga (2002a) 1.000 0.236 4.241 1.000 4 / 50 4 / 50
Braga (2002b) 0.886 0.338 2.323 0.806 10 / 50 11 / 50
Gianotti (2002) 0.764 0.424 1.376 0.370 30 / 102 36 / 102
Gunerhan (2009) 1.250 0.211 7.414 0.806 5 / 13 3 / 9
Mikagi (2011) 0.458 0.036 5.789 0.547 1 / 13 2 / 13
Aida (2014) 0.706 0.221 2.252 0.556 15 / 25 17 / 25
0.806 0.530 1.228 0.316
0.1 0.2 0.5 1 2 5 10
Favors IN Favors No Supp
Overall
A
B
C
D
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper No 
in means error limit limit p-Value IN Supp
Braga (2002a) -2.700 0.687 -4.047 -1.353 0.000 50 50
Bragal (2002b) -2.100 0.762 -3.594 -0.606 0.006 50 50
Gianotti (2002) -2.400 0.893 -4.151 -0.649 0.007 102 102
Horie (2006) -1.500 1.413 -4.269 1.269 0.288 33 34
Gunerhan (2009) 4.540 5.083 -5.422 14.502 0.372 13 9
Barker (2013) -1.700 1.123 -3.902 0.502 0.130 46 49
-2.220 0.395 -2.993 -1.447 0.000
-10.00 -5.00 0.00 5.00 10.00
Favors IN Favors No Supp
Overall
Figure 3. Forest plot results of meta-analysis of preoperative immunonutrition (IN) vs regular diet
without supplements. (A) Preoperative immunonutrition (IN) vs nosupplements (NoSupp) onwound
infection using random effects model. (B) Preoperative IN vs No Supp on infectious complications
using random effects model. (C) Preoperative IN vs No Supp on noninfectious complications using
randomeffectsmodel. (D) Preoperative IN vsNoSuppon lengthof stay using randomeffectsmodel.
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0.07; 95% CI, 2.29 to 2.43; p ¼ 0.96) (Fig. 2).
Preoperative immunonutrition vs no oral nutritional
supplements
In RCTs controlled with nonsupplemented standard diets,
preoperative IN was associated with decreased infectious
complications (OR ¼ 0.49; 95% CI, 0.30e0.83; p <
0.01) and LOS (mean difference 2.22; 95% CI, 2.99
to 1.45; p < 0.01). There was no statistically significant
reduction in noninfectious complications (OR ¼ 0.81;
95% CI, 0.53e1.23; p ¼ 0.32) or wound infections
(OR ¼ 0.69; 95% CI, 0.43e1.10; p ¼ 0.12) (Fig. 3).DISCUSSION
This meta-analysis demonstrates no significant difference
in effect of preoperative IN as compared with standard
ONS on postoperative clinical outcomes. Given the
high costs, poor palatability, and limited retail availability
of IN products, standard ONS can be a reasonable preop-
erative alternative. Standard ONS are inexpensive, widely
available, and manufactured by multiple vendors in a va-
riety of flavors to suite various tastes. Given the heteroge-
neity of the existing IN literature, the precise role of
preoperative IN has not been clearly defined. Our results
suggest that preoperative standard ONS is similar to IN.
The literature for postoperative IN is much stronger.
Postoperative IN has been demonstrated in many trials
and several meta-analyses to reduce infectious complica-
tions, ventilator days, and anastomotic leaks.4,24-29 The
theoretical grounding for IN is strong, particularly in con-
cert with an early enteral feeding algorithm.30 Arginine, one
of the key components of an IN strategy, is rapidly depleted
in surgery and after major metabolic stresses.6 Supplemen-
tation can promote cell growth and differentiation and
microvascular perfusion in these patients. Omega-3 fatty
acids in several perioperative randomized trials have been
demonstrated to modulate proinflammatory and anti-
inflammatory mediators in the heart, gut, liver, and in tu-
mor tissue.31-34 Antioxidants are typically the other key
ingredient in IN products. Preoperative antioxidants have
been shown to increase serum and tissue antioxidant levels,
but the clinical benefit is unclear.35 Because these are
combination products, it is challenging to sort out the ef-
fects of the various ingredients. The literature suggests
the synergism of effects by combining distinct immune-
modulating nutrients, especially arginine and fish oil.
Several other investigators have performed meta-analyses
examining various aspects of perioperative IN. Existing liter-
ature has often blurred the lines between preoperative, post-
operative, and perioperative (pre- and post-) regimens.36Many preoperative IN studies do not use isocaloric or isoni-
trogenous controls.37 Only one preoperative trial has ever
demonstrated a statistically significant reduction in infec-
tious complications when IN is compared with an isocaloric,
isonitrogenous control oral supplement.11 This trial and two
others without isonitrogenous controls also published by the
same group in the same year are responsible for much of the
signal of benefit detected in multiple previously published
meta-analyses.11,17,18 Other trials blend surgical, medical,
and mixed critical care populations. Because many pub-
lished studies do not clearly define or identify malnutrition
and focus on cancer populations, they represent trials of
nutrition vs malnutrition as much or more than they serve
as trials of IN vs standard supplements.
Perhaps the most widely cited meta-analysis is that of
Drover and colleagues in 2011.2 This study demonstrated
reduced infectious complications with preoperative IN,
but included trials with both isonitrogenous and standard
diet controls without a subanalysis of these groups. The
same year, Cerantola and colleagues published their
own meta-analysis with similar results, including a reduc-
tion in infectious and noninfectious complications and
LOS, also without any subanalysis of studies with
different types of controls.38
Recently, 4 small trials of preoperative IN have not
shown any benefit.15,16,21,22 Including some but not all of
the new trials, Osland and colleagues recently published
their own meta-analysis.3 Like the others, their meta-
analysis combined all trials examining preoperative supple-
mentation regardless of the type of control used. This
meta-analysis did, however, predate the larger Giger-Pabst
and colleagues16 and Hu¨bner and colleagues15 trials that
were performed with isocaloric, isonitrogenous controls.
Our meta-analysis attempts to reduce the heterogeneity
of the preoperative IN literature by clearly identifying
which studies use ONS controls vs those that use regular
nonsupplemented diets. As with other meta-analyses in
the nutrition literature, there are some inherent limita-
tions. Even when standard ONS controls were used, the
exact ingredients of these control formulas do vary from
study to study. Trials with nonsupplemented regular oral
diets were subject to the same variability. Many studies
failed to record patient compliance with supplements or
total protein intake (both from supplements and regular
diets). Most of the included studies used standard proto-
cols with a typical length of supplementation of 5 days,
but there was slight variation from study to study. Patients
receiving preoperative supplementation in some trials
might have received more monitoring in a nutrition sup-
port program resulting in improved outcomes.39 Although
IN is typically defined as nutrition with supplemental argi-
nine, fish oil, and antioxidants, most standard ONS
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The ideal dose of these immunonutrients has not been
defined and some standard ONS might contain therapeu-
tic concentrations of these ingredients. Each study we
included in our analysis was drawn from different patient
populations undergoing various operations. Populations
were randomized and controlled within each study, but
were not consistent across all of the studies analyzed. We
have used the random effects model approach to meta-
analysis to address the presence of this heterogeneity.
Despite these drawbacks, our meta-analysis of preoperative
IN provides new insights because of its focus on preoper-
ative IN only and the differentiation between trials
controlled with ONS vs regular nonsupplemented diets.
Commonly cited society guidelines supporting the use of
preoperative IN were created using the results of other
meta-analyses that did not account for this heterogeneity
as in the current meta-analysis.1,2
Preoperative supplementation with standard ONS has
not been studied extensively. Although our results suggest
the similarity of standard and immune-modulating supple-
ments, we cannot absolutely conclude that preoperative
standard ONS will result in improved outcomes. One study
evaluating preoperative supplementation with standard
ONS vs nonsupplemented control diet demonstrated less
postoperative weight loss and fewer minor complications
with preoperative supplementation.40 Several past studies
have failed to identify a major benefit from the use of stan-
dard preoperative ONS.41-43 This might be due to the lack
of a clear definition of “malnutrition” and inclusion of well-
nourished patients. Adherence to the new definitions of
malnutrition, as is being popularized by several societies,44
may serve to identify which patients will benefit the most
from preoperative supplements. Future studies of preopera-
tive nutrition should incorporate these new definitions.
Additionally, the varied composition and individual nutri-
ents of the standard ONS, particularly the amount and
biologic value of protein contained, might explain these
conflicting results. Dietary protein is critical to help
promote muscle protein synthesis and decrease
inflammation-associated loss of lean body mass and func-
tion. A meta-analysis by Cawood and colleagues of 36
RCTs (3,790 patients) showed that the use of high-
protein supplements (>20% of calories from protein)
was associated with reduced complications and readmis-
sion to hospital, improved grip strength, increased intake
of protein and energy, and improvements in weight.45CONCLUSIONS
Given the lack of a significant difference between IN and
standard ONS in the preoperative setting, and the factthat standard ONS are less expensive and widely avail-
able, we recommend use of standard ONS for nutritional
optimization of the surgical patient. Cost and accessibility
are key factors to patient compliance. As with smoking
cessation or exercise, achieving patient buy-in is crucial
to any successful preoperative optimization regimen.
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